Kodiak Sciences announced emerging durability data in patients with wet age-related macular degeneration (AMD) treated in its phase 1b clinical study of its investigational therapy KSI-301.
The results were presented by David M. Brown, MD, FACS, an investigator in the study, as a late-breaking oral presentation at The Retina Society Annual Meeting on September 15 in London. Dr. Brown is Clinical Professor of Ophthalmology at Baylor College of Medicine, Vice-Chair for Research at the Blanton Eye Institute, Houston Methodist Hospital, and Partner at Retina Consultants of Houston, Texas. The study findings presented by Dr. Brown can be found on the Kodiak Investor Relations website at http://ir.kodiak.com.
“The emerging durability data presented today suggest our objective for KSI-301 to be a leading next-generation anti-VEGF therapy with a long-interval durability profile is achievable,” Jason Ehrlich, MD, PhD, Kodiak’s Chief Medical Officer and Chief Development Officer, said in the news release. “In the presented cohort of treatment-naïve wet AMD patients followed for 12 weeks or longer after the loading phase, all achieved a treatment-free interval of three months or longer, with the majority reaching a 4- or 5-month interval and continuing to be followed without retreatment to date. While early, these durability and efficacy data, together with the continued promising safety data in over 250 injections and 100 patients, support our wet AMD ‘DAZZLE’ pivotal study design evaluating every 3-, 4- and 5-month dosing with KSI-301. Additional details of the phase 1b study results including durability of KSI-301 in retinal vein occlusion and diabetic macular edema are expected to be presented at the American Academy of Ophthalmology Retina Subspecialty Day on October 11. The DME and diabetic retinopathy severity data presented by Dr. Brown also highlight the potential for meaningful differentiation of KSI-301 in diabetic eye disease.”